• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

浸润性乳腺癌新辅助化疗的反应可通过 CD4+、CD8+ 和 FOXP3+肿瘤浸润淋巴细胞预测。

Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.

机构信息

Department of Anatomic Pathology, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National Hospital, Jakarta, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2024 May 1;25(5):1607-1613. doi: 10.31557/APJCP.2024.25.5.1607.

DOI:10.31557/APJCP.2024.25.5.1607
PMID:38809632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11318808/
Abstract

BACKGROUND

Response to neoadjuvant chemotherapy (NC) in individuals with invasive breast cancer (IBC) must be monitored, and biomarkers are needed. NC can activate an anti-tumour immune response in its microenvironment, known as Tumor-infiltrating Lymphocytes (TIL). TIL components believed to have great potential as predictors are CD4+, CD8+, and FOXP3+ TIL. This study aims to explore TIL components that can potentially be predictive biomarkers of NC pathological responses.

METHODS

A sample size of 40 were analyzed based on the relationship between CD4+, CD8+, and FOXP3+ TIL expression with the Miller-Payne (MP) grading system. Age, tumour grade, PR, ER, Ki-67, and HER2 were also evaluated. CD4+, CD8+, and FOXP3+ TIL expressions were analayzed by IHC staining, while other data were collected from archives. Data was analyzed using univariate and multivariate analysis.

RESULTS

Univariate analysis showed a significant relationship between CD4+ TIL and MP (p<0.001), CD8+ and MP (p=0.004), and FOXP3 with MP (p<0.001). The simultaneous integration of the three biomarkers in one model was not good enough to be a predictive model. Therefore, an exploratory analysis was conducted by testing several alternative models that combined two of the three existing biomarkers. It turned out that CD4+ TIL in model 2 (CD4+CD8+) and FOXP3+ TIL in model 4 (CD8+FOXP3+) showed significant coefficient values. Moreover, all of the threshold coefficients in model 4 are significant.

CONCLUSION

This study shows that CD4+, CD8+, and FOXP3+ TIL have promising potential as predictive biomarkers. In particular, FOXP3+ is dominant in predictive models of pathological response in patients with IBC.

摘要

背景

新辅助化疗(NC)治疗浸润性乳腺癌(IBC)的疗效必须进行监测,需要寻找生物标志物。NC 可在肿瘤微环境中激活抗肿瘤免疫应答,即肿瘤浸润淋巴细胞(TIL)。TIL 中的 CD4+、CD8+ 和 FOXP3+ 被认为具有成为预测标志物的巨大潜力。本研究旨在探讨 TIL 成分作为 NC 病理反应预测性生物标志物的潜在可能性。

方法

根据 CD4+、CD8+ 和 FOXP3+ TIL 表达与 Miller-Payne(MP)分级系统之间的关系,分析了 40 例样本。还评估了年龄、肿瘤分级、PR、ER、Ki-67 和 HER2。通过免疫组化染色分析 CD4+、CD8+ 和 FOXP3+ TIL 的表达,其他数据则从档案中收集。采用单变量和多变量分析进行数据分析。

结果

单变量分析显示,CD4+TIL 与 MP(p<0.001)、CD8+与 MP(p=0.004)和 FOXP3 与 MP 之间存在显著相关性(p<0.001)。将这三种生物标志物同时整合到一个模型中,不足以成为预测模型。因此,通过测试几种结合现有三种生物标志物中的两种的替代模型,进行了探索性分析。结果表明,模型 2(CD4+CD8+)中的 CD4+TIL 和模型 4(CD8+FOXP3+)中的 FOXP3+TIL 的系数值具有显著意义。此外,模型 4 中的所有阈值系数均具有显著意义。

结论

本研究表明,CD4+、CD8+ 和 FOXP3+ TIL 具有成为预测生物标志物的巨大潜力。特别是在 IBC 患者病理反应预测模型中,FOXP3+ 占据主导地位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f6c/11318808/f6a941c14d50/APJCP-25-1607-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f6c/11318808/f6a941c14d50/APJCP-25-1607-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f6c/11318808/f6a941c14d50/APJCP-25-1607-g001.jpg

相似文献

1
Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.浸润性乳腺癌新辅助化疗的反应可通过 CD4+、CD8+ 和 FOXP3+肿瘤浸润淋巴细胞预测。
Asian Pac J Cancer Prev. 2024 May 1;25(5):1607-1613. doi: 10.31557/APJCP.2024.25.5.1607.
2
Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.导管原位癌的免疫微环境:与乳腺浸润性癌的比较。
Breast Cancer Res. 2020 Mar 26;22(1):32. doi: 10.1186/s13058-020-01267-w.
3
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.评估曲妥珠单抗联合紫杉类药物新辅助治疗后 HER2 阳性乳腺癌中 PD-L1、肿瘤浸润淋巴细胞及 CD8+、FOXP3+免疫细胞的表达。
Breast Cancer Res Treat. 2020 Oct;183(3):599-606. doi: 10.1007/s10549-020-05819-8. Epub 2020 Jul 26.
4
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌新辅助化疗后残留肿瘤中肿瘤浸润性CD8 +和FOXP3 +淋巴细胞的预后意义及这些参数的变化:一项回顾性多中心研究
Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x.
5
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.乳腺癌患者新辅助化疗前后肿瘤浸润淋巴细胞亚群改变与新生血管生成的相关性
Int J Biol Markers. 2014 Sep 30;29(3):e193-203. doi: 10.5301/jbm.5000082.
6
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.肿瘤浸润淋巴细胞(TILs)的形态学评估以研究浸润性乳腺癌的免疫原性、揭示淋巴细胞网络并辅助复发预测:一项回顾性研究
Int J Mol Sci. 2017 Sep 8;18(9):1936. doi: 10.3390/ijms18091936.
7
Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.浸润性肿瘤 CD8/FOXP3 淋巴细胞比值预测侵袭性乳腺癌新辅助化疗的治疗反应。
Br J Surg. 2016 Jun;103(7):845-54. doi: 10.1002/bjs.10127. Epub 2016 Mar 8.
8
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.肿瘤浸润淋巴细胞、程序性细胞死亡配体-1、CD8 和 FOXP3 在三阴性乳腺癌预后模型中的整合:对 244 例接受标准治疗的 I-III 期患者的分析。
Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1.
9
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.肿瘤浸润免疫细胞谱及其在新辅助化疗后的变化可预测乳腺癌的反应和预后。
Breast Cancer Res. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5.
10
Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.乳腺癌患者不同阶段肿瘤浸润性T细胞的差异调控及功能
Tumour Biol. 2015 Sep;36(10):7907-13. doi: 10.1007/s13277-015-3507-y. Epub 2015 May 8.

本文引用的文献

1
Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?早期乳腺癌的多学科团队会议提案与最终治疗选择:是否存在共识?
Front Oncol. 2022 Jun 7;12:885992. doi: 10.3389/fonc.2022.885992. eCollection 2022.
2
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer.CD8 +淋巴细胞与肿瘤浸润性抑制性FOXP3 +效应调节性T细胞的比例与浸润性乳腺癌的治疗反应相关。
Discov Oncol. 2022 Apr 19;13(1):27. doi: 10.1007/s12672-022-00482-5.
3
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.
肿瘤微环境中免疫细胞的双重作用:促肿瘤和抗肿瘤作用及其触发因素。
Cancers (Basel). 2022 Mar 25;14(7):1681. doi: 10.3390/cancers14071681.
4
Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer.乳腺癌病理缓解的辅助化疗分析。
Comput Math Methods Med. 2021 Nov 15;2021:5440154. doi: 10.1155/2021/5440154. eCollection 2021.
5
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells.内质网应激诱导人卵巢癌细胞钙网织蛋白的释放和结合。
Cancer Immunol Immunother. 2022 Jul;71(7):1655-1669. doi: 10.1007/s00262-021-03072-6. Epub 2021 Nov 20.
6
The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study.乳腺癌新辅助化疗周期的选择在临床实践中具有重要意义:一项基于人群的真实世界研究结果
Cancer Biol Med. 2021 Oct 12;19(5):755-67. doi: 10.20892/j.issn.2095-3941.2020.0800.
7
The role of CD4 T cells in rejection of solid tumors.CD4 T细胞在实体瘤排斥反应中的作用。
Curr Opin Immunol. 2022 Feb;74:18-24. doi: 10.1016/j.coi.2021.09.005. Epub 2021 Oct 4.
8
The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.肿瘤浸润淋巴细胞和 CD8 表达作为预测非特殊型浸润性乳腺癌对蒽环类为基础的新辅助化疗反应的价值。
Breast Dis. 2021;40(S1):S9-S14. doi: 10.3233/BD-219002.
9
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.中性粒细胞与淋巴细胞比值、肿瘤浸润淋巴细胞(CD4+/CD8+)及程序性死亡配体 1 表达对胃癌患者预后及术前化疗反应的预测价值。
Cancer Immunol Immunother. 2022 Jan;71(1):45-55. doi: 10.1007/s00262-021-02960-1. Epub 2021 May 19.
10
High-mobility group box 1 serves as an inflammation driver of cardiovascular disease.高迁移率族蛋白 B1 可作为心血管疾病的炎症驱动因素。
Biomed Pharmacother. 2021 Jul;139:111555. doi: 10.1016/j.biopha.2021.111555. Epub 2021 Apr 15.